science wire

Scientists from the Universities of Bern, Zurich and Oxford as well as the Latvian Biomedical Research & Study Centre led by Prof. Martin F. Bachmann (University Clinic of Rheumatology, Immunoloy and Allergology, University of Bern) have developed a new therapeutic vaccine technology based upon enhanced virus like nanoparticle conjugates.

Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co.

Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, Honolulu, April 29 - May 3.

Phase III IMpower150 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin pl

EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients   Results demonstrate siponimod al

Tasigna (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy   New indication approved under FDA Prior

More than 4,000 people worldwide die from tuberculosis every day. This means the disease tops the list of the most common causes of death that result from a single pathogen.

Phase III IMpower131 study showed Roche's TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with

Virtually all mental health disorders come with difficulties in interpersonal relations that in the long run negatively affect the progression of the disease. The associated health an social restrictions can only be marginally improved by current forms of therapy. One of the reasons for this is that there has been very little research into the basic neurobiological principles and in particular the neurochemical mechanisms of these kinds of disorders.

Scientists at the University of Birmingham are set to receive a major cash boost for pioneering research into cancer. Cancer Research UK is planning to invest nearly £11m over the next five years in ground-breaking work being carried out by the University of Birmingham-based Cancer Research UK Clinical Trials Unit (CRCTU)*.

Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) , is the only therapy recommended by the guideline for patients unresponsive to antihistamine

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors First new medicine in over 20 years to treat people with haemophilia A with inhibitors in Europe Hemlibra d

Nowhere in the world have so many ocular tumours been irradiated with protons as at the Paul Scherrer Institute PSI.

Ultibro Breezhaler provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo     CLAIM is the first study to investigate the effect of dual bronchodilation on cardiac function   Data published in the Lancet Respiratory Medicine Basel, February 22, 2018 - Novartis today announced the publication of the CLAIM * study in the Lancet Respiratory Medicine, which demonstrated that trea

Majority of patients with scalp psoriasis on Cosentyx (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life   Scalp psoriasis affects 60 million people worldwide - a difficult-to-treat form of psoriasis with a substantial impact on quality of life -   Cosentyx data presented at AAD adds to robust evidence demonstrating sustained efficacy in plaque, nail, palmoplantar and scalp psoriasis as well as psoriatic

Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis Glatopa 40 mg/mL is a fully substitutable, AP-rated generic

Teenagers are far more critical users of social media than we give them credit for, and need to be better supported in reaping the benefits social media can have.

US label updated to include Cosentyx (secukinumab) data in moderate-to-severe scalp psoriasis - one of the difficult-to-treat types of psoriasis   Approximately half of all 125 million patients with

Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cance

Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL Analysis of 75 patients with m

Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT)   Advanced Accelerator Applications is a newly established subsidiary of Novartis   Lutathera expands Novartis' n

Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hem

Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto , more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1 bi

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss Novartis enters into a licensing and supply agre

Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments LIBERTY is the first mi

Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy   EMA granted accelerate

Results from CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara * (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks Data support findings from the CLEAR study, which found Cosentyx was superior to Stelara * in achieving sustained skin clearance (PASI 90) at 52 weeks Cosentyx is the first and only fully human interleukin-17A (IL-17A) inhibitor that showed sustained skin cleara

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS) EXCEED is the first head-to-head superiority trial versus Humira * in psoria

New technology allows better testing and monitoring of HIV patients living in remote settings For the first time, patient plasma samples no longer need refrigeration during transport to the lab Card

Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of

Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in preor perimenopausal women who received no prior endocrine therapy for advanced disease Treatment benefit with K

Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma Priority Review designation based on Phase I

Inclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP   Deep and sustained molecular response included as key eligibility criteria for atte

European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSC

A trial designed and co-ordinated by the University of Birmingham's Cancer Research UK Clinical Trials Unit to test an experimental drug in patients with head and neck cancer has launched today through the Combinations Alliance - a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network.

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated c